Sleven, I agree with those points. When this topic was raised a few months ago (or at some point, I don't recall), someone here indicated that the FDA would not accept Japanese study data. This is why I felt that a short safety trial would be required.
It would be fantastic if the FDA did accept that trial data. I just don't have enough knowledge to determine whether that would be the case or not.
But I have zero concerns about safety. Just trying to look forward at potential timelines that Amarin may be looking at.
Market Data 
Markets 
AI
